NIOX® approved in China. Aerocrine expands its distribution agreement to include NIOX MINO®.

NIOX® approved in China.  Aerocrine expands its  distribution agreement to
include NIOX MINO®.

SOLNA - 7  December 2007 - Aerocrine AB (OMX Nordic Exchange: AERO) announces
that the company's NIOX product has been approved by SFDA, the Chinese
registration authority. Aerocrine has also entered into a distribution agreement
with Bioson Inc. that includes sales of both NIOX and NIOX MINO in China.

NIOX is the first device for managing airway inflammation by measuring exhaled
NO, that is approved for clinical use and marketing in China. Aerocrine and
Bioson Inc. entered into collaboration in 2004 for distributing NIOX on the
Chinese market. This agreement has now been expanded to include NIOX MINO. 

Today, about five percent of teenagers in China have asthma symptoms and the
corresponding adult figure is two percent. Around 40 million Chinese have asthma
and this figure is increasing rapidly due to worsened environmental conditions
and improved possibilities for diagnosis. The Chinese market for asthma drugs is
estimated to increase from SEK 1.2 billion in 2006 to SEK 2.3 billion in 2011.
China represents a significant future prospect for Aerocrine. 

Bioson is a well-established company with its head office in Beijing and
branches in 32 provinces. Bioson currently sells medical products to over 70
percent of all hospitals in China. Bioson is known for its high-quality
products, service and support. Bioson is one of nine Chinese medical-technical
companies that are selected partners of the Chinese Medical Association. 

For more information, contact:

Paul de Potocki, President & CEO, telephone: +46 8 629 07 82

Aerocrine discloses the information provided herein pursuant to the Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 08:00 AM on December 7, 2007.

About Aerocrine
Aerocrine AB is a clinically based medical technology corporation dedicated to
improved asthma management and care. Aerocrine was listed on the Stockholm Stock
Exchange on 15 June, 2007. The company is marketing NIOX® Flex on a worldwide
basis and is also marketing NIOX MINO®, representing a new generation of
hand-held devices, in Europe. Both products are tailored for rapid, non-invasive
control of the inflammatory status in the airways and may play a critical role
for optimized asthma care and disease control. Aerocrine is located in Sweden
with wholly owned subsidiaries in the US, UK and Germany.